Last reviewed · How we verify
NCT04335045
Phase I Study of PH100 (Ecklonia Cava Phlorotannins)
Phase 1 trial testing Placebo in Safety Issues in 48 participants. Completed in 8 December 2014.
8 December 2014
Quick facts
| Lead sponsor | Phloronol Inc. |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 48 |
| Start date | 25 September 2013 |
| Primary completion | 8 December 2014 |
| Estimated completion | 8 December 2014 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Placebo
- PH100 100mg
- PH100 200mg — full drug profile →
- PH100 400mg — full drug profile →
- PH100 800mg — full drug profile →
- PH100 1200mg — full drug profile →
- PH100 1600mg — full drug profile →
Conditions studied
- Safety Issues — all drugs for Safety Issues →
Sponsor
Phloronol Inc. — full company profile →
Who can join
Adults 40 to 75, any sex, with Safety Issues. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study was to determine the safety and tolerability of PH100, a purified phlorotannins from a brown alga Ecklonia cava and the pharmacokinetics of its major compounds 8,8'-bieckol, dieckol, and phlorofucofuroeckol A (PFF-A), after single, ascending, oral doses of PH100 Capsules (over-encapsulated tablets) in healthy adult volunteers.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Docking and <i>in silico</i> toxicity assessment of <i>Arthrospira</i> compounds as potential antiviral agents against SARS-CoV-2.
Petit L, Vernès L, Cadoret JP. · · 2021 · cited 22× · PMID 33776210 · DOI 10.1007/s10811-021-02372-9
Verify or expand the search:
- PubMed search for NCT04335045
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Safety Issues
Currently open trials in the same condition.
- NCT06485141 — BeSMART Secure Storage Counseling in the Inpatient Setting · NA · recruiting
- NCT06494527 — A Phase 1 Study to Evaluate the Safety/Tolerability, PK/PD of RG002C0106 Injection in Healthy Adults · Phase 1 · active not recruiting
- NCT06189170 — Phase I Study to Evaluate KP405 in Healthy and Parkinson's Disease Patients · EARLY_PHASE1 · recruiting
- NCT06509490 — NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors · NA · recruiting
- NCT06498167 — Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib) · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04335045 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Phloronol Inc.
- Last refreshed: 6 April 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04335045.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing